Skyhawk Therapeutics Announces Positive First Interim Results in Patients from its Phase 1 Clinical Trial of SKY-0515 as a Treatment for Huntington’s Disease
SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering…
Majority of Global Employers Remain Unprepared for Pay Transparency Laws, Aon Finds
Organizations remain focused on compliance rather than embracing transparency as a strategic…
Despite Global Headwinds, Domestic Demand and Prudent Investment drive Small Business Optimism- ASSOCHAM-Dun & Bradstreet’s Small Business Confidence Index
MUMBAI, India, June 13, 2025 /PRNewswire/ -- ASSOCHAM along with Dun & Bradstreet,…
ERA Congress: Long-term data show sustained efficacy and safety of zigakibart in patients with IgA nephropathy
VIENNA, June 5, 2025 /PRNewswire/ -- New 100-week data from the ongoing…